Table 1.
Baseline characteristics in survivors versus non-survivors. Data are reported as numbers (percentages) or mean ± standard deviationas appropriate. p-value: for the comparison between survivors vs. non-survivors. BMI: body mass.
| Survivors (n = 15) |
Non-Survivors (n = 15) |
p-Value (α: 0.05) | |
|---|---|---|---|
| Age (years) | 61 ± 9 | 71 ± 8 | 0.04 |
| Male sex, no. (%) | 12 (80) | 12 (80) | ˃0.99 |
| BMI (kg/m2) | 28 ± 4 | 28 ± 4 | ˃0.99 |
| Comorbidities, no. (%) | |||
| Hypertension | 7 (47) | 11 (73) | 0.15 |
| Dyslipidemia | 2 (13) | 4 (27) | 0.65 |
| Former smoker | 2 (13) | 7 (47) | 0.11 |
| Diabetes type 2 | 3 (20) | 2 (13) | ˃0.99 |
| Prior MI | 0 (0) | 2 (13) | 0.48 |
| Prior coronary revascularization | 0 (0) | 2 (13) | 0.48 |
| Prior CVA | 0.07 (0.2) | 0 (0) | 0.33 |
| Peripheral artery disease | 1 (7) | 5 (33) | 0.17 |
| Chronic coronary syndrome | 0 (0) | 2 (13) | 0.48 |
| Transient ischemic attack (mini stroke) | 1 (7) | 0 (0) | ˃0.99 |
| Atrial flutter | 2 (13) | 2 (13) | ˃0.99 |
| CHA₂DS₂-VASc score for atrial fibrillation stroke risk (≥ 2) | 6 (40) | 11 (73) | 0.14 |
| Other CVD | 1 (7) | 1 (7) | ˃0.99 |
| Chronic kidney disease | 3 (20) | 8 (53) | 0.13 |
| Cancer | 2 (13) | 4 (27) | 0.65 |
| Home medical therapy, no. (%) | |||
| Aspirin | 0 (0) | 3 (20) | 0.22 |
| Statins | 2 (13) | 5 (33) | 0.39 |
| ACE inhibitors | 4 (27) | 9 (60) | 0.26 |
| Beta-blockers | 2 (13) | 5 (33) | 0.39 |
| Calcium channel blockers | 2 (13) | 5 (33) | 0.39 |
| Diuretics | 1 (7) | 5 (33) | 0.17 |
| Glucose drugs | 1 (7) | 1 (7) | ˃0.99 |